LONDON – Gene therapy is moving on from rare inherited diseases and going mainstream in a potential $2 billion-plus deal between Uniqure NV and Bristol-Myers Squibb Co., (BMS) to develop treatments for cardiovascular diseases. Read More
Getting a drug through today's rigorous and costly development and regulatory processes – a 2014 Tufts study estimated more than a decade and $2.6 billion in expenses – might seem like the endgame. But the next step, getting that drug into the hands of doctors and patients, is just as crucial, and that's where a successful direct-to-consumer (DTC) marketing campaign could make the difference between a market leader and an also-ran. Read More
BOGOTA, Colombia – New updates to Brazil's health care legislation could have a major impact on the pharmaceutical sector. In January, Brazil's Congress passed a series of legal amendments that could cut red tape for drug developers looking to expand their manufacturing operations in the country. Read More
Cachexia, the weight loss and wasting that is a feature of some types of cancer, as well as AIDS and certain other diseases, was once seen as a quality-of-life issue. Read More
NEW DELHI – India is taking a series of steps to power its biopharmaceutical industry that could lead to more investment, better infrastructure for drug development and a visible reduction in red tape. One of the more significant such steps is the development of a series of biotech and pharmaceutical industry clusters that could help speed up drug discovery and development. Read More
The old adage "you get what you pay for" may not hold true for new cancer drugs. A study of cancer drugs approved by the FDA between 2009-2013 shows little correlation between the efficacy of a drug and its price tag. Read More
Insmed Inc., of Bridgewater, N.J., said it closed its $237.5 million public offering of 11.5 million shares, including 1.5 million shares sold to cover overallotments, at a price of $20.65 per share. Read More
Cytori Therapeutics Inc. reported that the CFDA has granted Lorem Vascular, Cytori's exclusive licensee in the region, regulatory clearance to market its Celution product, a system for extracting specialized cells, including stem cells from, adult patients' own fat tissue. Read More
Icon Bioscience Inc., of Sunnyvale, Calif., said phase III data showed significantly positive outcomes for IBI-10090 compared to placebo in treating inflammation associated with cataract surgery. Read More
Shire plc, of Dublin, acknowledged two petitions filed with the Patent and Trademark Office on April 2 by Hayman Capital Management regarding Lialda (mesalamine) and Gattex (teduglutide [rDNA origin]) and said it will pursue all legal options and vigorously defend its patents, which are listed in the FDA Orange Book. Read More
